SCHEMBL6612970

SCHEMBL6612970

CC(=O)Nc1ccc(-c2sccc2NS(=O)(=O)c2cc(Cl)c(Cl)cc2Cl)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.43
PIK3CG P48736 2/20 0.43
PIK3C3 Q8NEB9 2/20 0.43
MAPK1 P28482 2/20 0.43
GAA P10253 1/20 0.43
ATM Q13315 1/20 0.43
ALDH1A1 P00352 2/20 0.42
IDO1 P14902 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 2/20 0.41
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GUSB P08236 1/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.39
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20899642 0.85 ACLY (0.42) PIK3CDPIK3CGPIK3C3MAPK1GAA
SCHEMBL6623115 0.84 ATM (0.51) MAPK1ATMALDH1A1IDO1MEN1
SCHEMBL6610826 0.83 ATM (0.65) PIK3C3MAPK1GAAATMALDH1A1
SCHEMBL6612002 0.81 ATM (0.45) MAPK1ATMALDH1A1IDO1MEN1
SCHEMBL6611750 0.80 PIK3CD (0.43) PIK3CDPIK3CGPIK3C3MAPK1GAA
SCHEMBL6612444 0.79 HSD11B1 (0.46) PIK3C3GAAIDO1MEN1KMT2A
SCHEMBL6615002 0.79 MAPT (0.46) MAPK1GAAATMALDH1A1IDO1
SCHEMBL6691336 0.77 HTT (0.57) GAAIDO1MEN1KMT2APKM
SCHEMBL6614559 0.77 GUSB (0.50) MEN1KMT2AMAPTGUSBPOLB
SCHEMBL2762593 0.76 MAPT (0.65) MAPK1GAAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO disclosed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 PIK3CD 1876/4885PIK3CG 2713/4885PIK3C3 3219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.